BRCA 1 & 2, ATM, BARD1, CDH1, CHEK2, MRE11A, NBN, p53, PALB2, PTEN, RAD50, RECQL, RINT1, and possibly MSH6 and PMS2 genes
Posted on: Oct 23, 2019 12:04PM
Multigene Testing of Everyone Diagnosed With Breast Cancer Deemed Cost-Effective, and Researchers Say Policies Should Change
October 8, 2019
A study found testing all people diagnosed with breast cancer for mutations in three genes linked to a high risk of the disease — BRCA1, BRCA2, and PALB2 — would be "extremely cost-effective" compared to testing based on family history or clinical guidelines in the United States and the United Kingdom. Read more...